Lifei Xiaoji Wan

PreclinicalSmall molecule

HHenan University of Traditional Chinese Medicine

Lifei Xiaoji Wan is one of 53 small molecule programs targeting Advanced NSCLC. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Advanced NSCLCRecruiting

Tumor MicroenvironmentRecruiting

Advanced NSCLCPreclinical

Recruiting

Tumor MicroenvironmentPreclinical

Recruiting

Competition

Competitive Landscape

60 competitors in Advanced NSCLC

#DrugCompanyPhaseTrials

Beyfortus

BeiGene

Approved

3 2

Tagrisso

AstraZeneca

Phase 3

4 3

Taxotere

AAvyxa

Phase 3

12 4

Alimta

SShawn Eagle

Phase 3

8 5

Paraplatin

AAvyxa

Phase 3

8 6

Tarceva

OOSI Pharmaceuticals

Phase 3

7 7

Keytruda

Merck & Co.

Phase 2

7 8

Opdivo

Bristol-Myers Squibb

Phase 2

6 9

Taxol

Teva

Phase 2

6 10

Avastin

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Advanced NSCLC1 trial

Lifei Xiaoji Wan in Treatment of Advanced NSCLC

Recruiting·HHenan University of Traditional Chinese Medicine·N/A·NCT06406166·100 enrolled

Tumor Microenvironment1 trial

Lifei Xiaoji Wan Treatment's of Early-stage NSCLC and Its Impact on the Tumor Microenvironment

Recruiting·HHenan University of Traditional Chinese Medicine·N/A·NCT06387134·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Lifei Xiaoji Wan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lifei Xiaoji Wan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lifei Xiaoji Wan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Henan University of Traditional Chinese Medicine company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: HHenan University of Traditional Chinese Medicine

Lifei Xiaoji Wan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Advanced NSCLC1 trial

Tumor Microenvironment1 trial

References

Drug Info

Quick Facts

Related News